- Trials with a EudraCT protocol (44,393)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,393 result(s) found.
Displaying page 1,623 of 2,220.
| EudraCT Number: 2019-001756-19 | Sponsor Protocol Number: MTP-2019-01 | Start Date*: 2019-12-11 |
| Sponsor Name:María de los Ángeles Tena Pajuelo (Investigador independiente) | ||
| Full Title: MULTI-CENTER, DOUBLE-BLIND, CONTROLLED, PARALLEL AND RANDOMIZED STUDY TO COMPARE THE EFFECTIVENESS OF 0.1 ΜG / KG / MIN OF LEVOSIMENDAN VERSUS PLACEBO IN THE POSTOPERATIVE OF CARDIAC PROGRAMMED SUR... | ||
| Medical condition: Patients who have preoperatively severe left ventricular dysfunction (LVEF ≤ 35%) and will be scheuled for cardiac surgery on cardiopulmonary bypass. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-002125-38 | Sponsor Protocol Number: DAPA-ESR-16-12460 | Start Date*: 2018-11-19 | |||||||||||
| Sponsor Name:LM Diagnósticos S.L. | |||||||||||||
| Full Title: Effect of dapagliflozin on nighttime blood pressure in type 2 diabetes | |||||||||||||
| Medical condition: Patients with diabetes and high blood pressure | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-003288-36 | Sponsor Protocol Number: COMP001 | Start Date*: 2018-03-09 | ||||||||||||||||
| Sponsor Name:COMPASS Pathways, Ltd | ||||||||||||||||||
| Full Title: The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression (P-TRD) | ||||||||||||||||||
| Medical condition: Treatment-Resistant Depression (P-TRD) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) PT (Completed) NL (Completed) IE (Completed) DK (Completed) ES (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-004453-71 | Sponsor Protocol Number: AMLSG31-19 | Start Date*: 2022-02-01 |
| Sponsor Name:University Hospital Ulm | ||
| Full Title: A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrom... | ||
| Medical condition: AML or MDS-EB2 | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-002619-89 | Sponsor Protocol Number: B1761031 | Start Date*: 2019-06-05 | |||||||||||
| Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
| Full Title: A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG™) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTOR... | |||||||||||||
| Medical condition: relapsed or refractory CD33-positive acute myeloid leukaemia (AML) | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000598-95 | Sponsor Protocol Number: HS-20-674 | Start Date*: 2021-07-30 | |||||||||||
| Sponsor Name:Camurus AB | |||||||||||||
| Full Title: A Phase 2, randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acute respiratory distress ... | |||||||||||||
| Medical condition: Acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-002816-29 | Sponsor Protocol Number: 205207 | Start Date*: 2019-06-17 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
| Full Title: A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Multiple Myeloma (... | |||||||||||||
| Medical condition: Relapsed/Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002464-14 | Sponsor Protocol Number: GEIS-39 | Start Date*: 2017-03-02 |
| Sponsor Name:Grupo Español de Investigación en Sarcomas (GEIS) | ||
| Full Title: Phase II trial of nab-paclitaxel for the treatment of desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma | ||
| Medical condition: Cohort 1: Subjects with desmoid tumor Cohort 2: Subjects with desmoplastic small round cell tumor or Ewing sarcoma | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-004733-17 | Sponsor Protocol Number: XAMNPEAP2019 | Start Date*: 2020-02-25 | |||||||||||
| Sponsor Name:Aurora Pujol Onofre | |||||||||||||
| Full Title: Effect of plasma exchange by albumin replacement in Adrenomyeloneuropathy: unicentric, single arm, proof of concept trial | |||||||||||||
| Medical condition: Adrenomyeloneuropathy | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002037-15 | Sponsor Protocol Number: SARTRE | Start Date*: 2020-05-25 |
| Sponsor Name:Cristina Avendaño Sola | ||
| Full Title: Multicenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized Patients | ||
| Medical condition: SARS-CoV-2 infected patients with pneumonia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-001442-19 | Sponsor Protocol Number: IIBSP-COV-2020-23 | Start Date*: 2020-04-02 |
| Sponsor Name:INSTITUT DE RECERCA H. SANTA CREU I SANT PAU | ||
| Full Title: Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19) | ||
| Medical condition: COVID19 | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-006852-37 | Sponsor Protocol Number: CPKC412A2301 | Start Date*: 2008-07-11 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A phase III randomized, double-blind study of induction(daunorubicin/cytarabine)and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients <... | |||||||||||||
| Medical condition: newly diagnosed FLT3 mutated acute myeloid leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) SK (Completed) HU (Completed) BE (Completed) IT (Completed) FR (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-003023-30 | Sponsor Protocol Number: 401GSDIA01 | Start Date*: 2018-11-27 | |||||||||||
| Sponsor Name:Ultragenyx Pharmaceutical, Inc. | |||||||||||||
| Full Title: A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6-Phosphatase (G6Pase) in Adults with Glycogen Storage Dise... | |||||||||||||
| Medical condition: Glycogen Storage Disease Type Ia (GSDIa). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003117-18 | Sponsor Protocol Number: HUB-INF-ALBUCAP-402 | Start Date*: 2019-07-10 | |||||||||||
| Sponsor Name:Dr. Jordi Carratalà Fernández (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge | |||||||||||||
| Full Title: A phase III randomized, controlled, open label multicenter clinical trial, with two parallel groups, to evaluate the efficacy of albumin administration in patients hospitalized with community-acqui... | |||||||||||||
| Medical condition: Community-acquired pneumonia (CAP) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-000911-25 | Sponsor Protocol Number: BST-LT-01 | Start Date*: 2019-02-12 | |||||||||||
| Sponsor Name:Banc de Sang i Teixits | |||||||||||||
| Full Title: A prospective multicenter open, not controlled phase Ib-II clinical trial to assess the safety and immunologic efficacy of virus-specific T lymphocytes from the best donor in receptors of hematopoi... | |||||||||||||
| Medical condition: CMV viral infection in an immunocompromised host | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001505-22 | Sponsor Protocol Number: BST-COVID-01 | Start Date*: 2020-04-23 | |||||||||||
| Sponsor Name:Banc de Sang i Teixits | |||||||||||||
| Full Title: Double-blind, randomized, parallel, placebo-controlled pilot clinical trial, nested in a prospective cohort observational study, for the evaluation of the efficacy and safetyof two doses of WJ-MSC ... | |||||||||||||
| Medical condition: Acute respiratory distress syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-001645-64 | Sponsor Protocol Number: CA209-714 | Start Date*: 2016-10-25 | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcin... | |||||||||||||
| Medical condition: Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) ES (Completed) IE (Completed) BE (Completed) NL (Completed) SE (Completed) NO (Completed) GB (GB - no longer in EU/EEA) FI (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-007795-23 | Sponsor Protocol Number: CD-2009-01 | Start Date*: 2010-09-13 | |||||||||||
| Sponsor Name:Instituto Cientifico y Tecnologico de Navarra | |||||||||||||
| Full Title: ESTUDIO FASE II ALEATORIO CON INMUNOTERAPIA MEDIANTE CÉLULAS DENDRÍTICAS EN PACIENTES CON METÁSTASIS HEPÁTICAS RESECADAS DE CARCINOMA COLORRECTAL | |||||||||||||
| Medical condition: Carcinoma colorrectal con metástasis hepáticas tratadas con neoadyuvancia y resección quirúrgica completa | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-001992-30 | Sponsor Protocol Number: | Start Date*: 2015-04-20 | |||||||||||
| Sponsor Name:University of Leicester | |||||||||||||
| Full Title: A randomised controlled phase II trial of oral vinorelbine as second line therapy for patients with malignant pleural mesothelioma | |||||||||||||
| Medical condition: Histologically confirmed malignant pleural mesothelioma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-006051-12 | Sponsor Protocol Number: ICORG 06-03 | Start Date*: 2007-04-04 | |||||||||||
| Sponsor Name:ICORG | |||||||||||||
| Full Title: PHASE II TRIAL OF THE MULTI-DRUG RESISTANCE PROTEIN MODULATING AGENT SULINDAC IN COMBINATION WITH EPIRUBICIN IN PATIENTS WITH ADVANCED MELANOMA | |||||||||||||
| Medical condition: Metastatic malignant melanoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.